Skip to main content

Cannabidiol (CBD) for the management of Cannabis withdrawal, test for THC, THC-COOH and CBD in 35 urine and 15 blood samples

Project Member(s): Fu, S.

Funding or Partner Organisation: University of New South Wales

Start year: 2014

Summary: The main purpose of the research is to measure the level of cannabidiol (CBD) and tetrahydrocannabinol (THC) in blood and urine of patients receiving CBD for cannabis detoxification treatment. Analytical methods published in literature will be followed. The blood and urine samples will be coded and delivered to UTS by the external researchers and we report drug concentrations to the coded sample ID at the end of the project back to the external researchers. If THC and its metabolites are found in the sample, the patients would have taken cannabis concurrently and should not be included in the evaluation of the efficiency of the trial.


Pokorski, I, Clement, N, Phung, N, Weltman, M, Fu, S & Copeland, J 2017, 'Cannabidiol in the Management of In-Patient Cannabis Withdrawal: Clinical Case Series', Future Neurology, vol. 12, no. 3, pp. 133-140.
View/Download from: Publisher's site

Keywords: cannabidiol (CBD), tetrahydrocannabinol (THC)

FOR Codes: Diagnostic Methods, Toxicology (incl. Clinical Toxicology), Toxicology (incl. clinical toxicology) , Provision of health and support services not elsewhere classified, Diagnosis of human diseases and conditions